Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II first-line chemotherapy plus TG4010 and nivolumab in advanced non-squamous NSCLC
2016-005115-41Phase 2Completed
- Sponsor
- Transgene SA
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TG4010, nivolumab in Non-small cell lung cancer (NS-NSCLC), sponsored by Transgene SA. Started Jun 2017; status: completed.
02
Drugs
TG4010nivolumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on 2016-005115-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005115-41.